Andrew Powaleny
Andrew Powaleny is the Deputy Vice President of Public Affairs at PhRMA, where he leads communications on scientific, regulatory and intellectual property issues, highlighting the biopharmaceutical industry’s efforts in developing innovative medicines and vaccines while promoting an environment that encourages necessary risk-taking. For five years starting in 2019, he launched and led PhRMA’s grassroots initiative, Voters for Cures, bringing patients and caregivers together to advocate for access to medicine and biopharmaceutical innovation. He also co-founded and co-chaired PRIDE Umbrella, a resource group for LGBTQ+ individuals. Prior to joining PhRMA in 2015, Andrew worked as a communications consultant in Washington, D.C., and as Deputy Press Secretary for the U.S. House Committee on Energy and Commerce under Chairman Fred Upton. He holds a degree in public policy and government from Eastern Connecticut State University, with a minor in music. Outside of work, Andrew enjoys exercise, musical theater and mentoring college students through The Fund for American Studies alumni association.
Setting the record straight: 3 facts about drug patents
ICYMI: Measles resurgence could cost U.S. nearly $8 billion over five years
Key context is often missing from the debate over the Patent Trial and Appeal Board
How post-approval innovation keeps delivering for patients
New study: Measles setbacks harm health and America’s economy
Three things to know about Bayh-Dole: Innovation that pays off for taxpayers
Why the vaccine injury program matters
New report: How intellectual property drives U.S. innovation and biopharma's impact
New report: Post-approval innovation delivers substantial patient benefits
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
From sound to science: How IP powers innovation in music and hearing
3 myths critics get wrong about intellectual property
ICYMI: PhRMA submits comments to White House on artificial intelligence
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
Leveraging the power of vaccines to prevent antimicrobial resistance
New research: American biopharmaceutical investment in R&D drives transformational innovation
Three things to know about the United Nations’ new HIV/AIDS report
New analysis: Accelerated approval pathway is changing lives in underserved communities
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
Watch: Putting patients front and center for World AIDS Day
Three things economists are saying about the Inflation Reduction Act
New 340B Mega Guidance
New report shows how the Inflation Reduction Act stifles innovation for small molecule medicines
Biopharmaceutical science powered by PRIDE
Reject efforts to undermine America’s R&D ecosystem
Setting the record straight on accelerated approval
Mental Health Awareness Month: Fighting the growing mental health crisis and supporting innovation
IRA Impacts: Cancer treatment research and development
What we’ve learned from three years of fighting COVID-19
Novel medicines approved in 2022 offer increased treatment options for patients
What they are saying: PASTEUR Act can help fight antimicrobial resistance
Mental Illness Awareness Week – A time for reflection
Timely reauthorization of PDUFA and BsUFA is vital to the FDA’s review of medicines
ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines
The Patient Perspective: Government price-setting harms patients
Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Recognizing LGBTQ+ Pride in biopharmaceutical science
Report: More than 500 medicines in development to treat disorders of the blood
ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19
The accelerated approval pathway: Helping patients with serious or life-threatening diseases
4 things to know about biopharmaceutical efforts to fight cancer
New data show continued decline in death rates for cancer patients related to treatment advances
Post-approval research save lives. Why is Congress trying disincentivize it?
New Report: Nearly 800 new medicines in development to treat rare diseases
3 things to know about the importance of post-approval research and development
World AIDS Day: Remembering those we’ve lost and exploring the continued fight against HIV/AIDS
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
New report shows more than 260 medicines in development to fight neurodegenerative diseases
Meeting Tomorrow: Looking ahead to PDUFA VII
The impact of monoclonal antibodies and COVID-19 recovery
Recognizing Hepatitis R&D on World Hepatitis Day
Watch: Building trust and enhancing clinical trial diversity
More than 800 medicines are in development for diseases that disproportionately affect racial and ethnic communities
Researchers to shine light on biopharmaceutical R&D with policymakers
ICYMI: PhRMA president and CEO Stephen J. Ubl joins other industry leaders for a conversation on COVID-19 vaccines with Axios
How strengthening the biosimilar marketplace benefits patients
Reflecting on Mental Health Awareness Month
New PhRMA report shows nearly 90 medicines in development to fight drug-resistant infections
ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures
ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
2020 FDA approvals show innovation despite COVID-19 pandemic challenges
ICYMI: Cancer death rate continues decline due to advances in treatment
Report: More than 1,300 medicines and vaccines in development to help fight cancer
Leading researchers to spotlight the critical role of biopharmaceutical R&D
Summer reading in the age of COVID-19
The patient perspective navigating COVID-19
ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19
What scientific experts are saying about vaccine safety
New report shows nearly 260 vaccines in development, including dozens for COVID-19
Merck’s Dr. Julie Gerberding on the threat of antimicrobial resistance and COVID-19
ICYMI: America’s biopharmaceutical companies are taking on COVID-19
Nearly 400 cell and gene therapies in development to target a broad range of diseases
ICYMI: Continued biopharmaceutical action on COVID-19
ICYMI: 2019 brings innovative medicines to patients
R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures
Event tomorrow: Maintaining America’s leadership in access and innovation
Nearly 140 medicines in development to treat mental illness
IP Explained: Understanding biopharmaceutical innovation
Event tomorrow: Improving access and affordability for America’s seniors
New report shows more than 160 medicines in development for diabetes and related conditions
New report shows nearly 20 innovative medicines in development for sickle cell disease
130 medicines in development for asthma, allergies and other respiratory diseases
130 medicines in development for asthma, allergies and other respiratory diseases
Putting 2018 medicine approvals in context
New report shows nearly 300 cell and gene therapies in development
World AIDS Day 2018: Hope for the future
New report shows more than 300 skin disease medicines in development
Disrupting Alzheimer's
Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines
Event next week: Supporting the next generation of lifesaving medicines
Nearly 60 biopharmaceutical researchers GoBoldly on Capitol Hill
Diversity of thought fuels next generation of breakthroughs
New report and resources put cancer in context, showing more than 1,100 medicines and vaccines in development
Event tomorrow: Improving patient access to lifesaving medicines
A new era in Alzheimer’s innovation
New report shows over 500 medicines in development for neurological disorders
Rare Disease Day: Unmet need inspires innovation
New report shows 200 medicines in development for heart disease and stroke
ICYMI: Why 2017 medicine approvals matter
ICYMI: Report highlights increasing prevalence for Alzheimer’s disease
World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation
Supporting opportunities for enhanced competition in the marketplace
Honoring veterans serving in the biopharmaceutical industry
New report and event examine the new era of vaccines
A new era in cancer
PhRMA, member companies and NIH create public-private partnership for immuno-oncology
How biopharmaceutical collaboration is driving a new era of medicine
Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation
Why reauthorization of PDUFA matters
More than 50 medicines and vaccines in development for HIV infection, treatment and prevention
Examining the brain in The New Era of Medicine
Opening the conversation around mental health treatment with advocates & industry leaders
Celebrating PRIDE in biopharmaceutical science
More than 240 immuno-oncology treatments in development to fight cancer
ICYMI: New study shows medicines advance life expectancy for HIV patients
Clinical Trials Awareness Week: Celebrating the impact of clinical research
ICYMI: The New Era of Medicine initiative spotlights genomics in NYC
A new era in genomics
ICYMI: Report highlights overall decrease in cancer death rates
ICYMI: New era of medicine initiative kicks off in Boston
Watch: Biomarkers in drug development with Dr. Bernie Zeiher
The 20-year journey yielding a new weapon against cancer
3 things to know about 2016 drug approvals
Andrew Powaleny